- Home
- RIGL vs TKNO Comparison
RIGL vs TKNO Comparison
Compare RIGL & TKNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- TKNO
- Stock Information
- Founded
- RIGL 1996
- TKNO 1996
- Country
- RIGL United States
- TKNO United States
- Employees
- RIGL N/A
- TKNO N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- TKNO Medicinal Chemicals and Botanical Products
- Sector
- RIGL Health Care
- TKNO Health Care
- Exchange
- RIGL Nasdaq
- TKNO Nasdaq
- Market Cap
- RIGL 335.5M
- TKNO 256.9M
- IPO Year
- RIGL 2000
- TKNO 2021
- Fundamental
- Price
- RIGL $38.85
- TKNO $4.35
- Analyst Decision
- RIGL Buy
- TKNO
- Analyst Count
- RIGL 5
- TKNO 0
- Target Price
- RIGL $38.20
- TKNO N/A
- AVG Volume (30 Days)
- RIGL 995.6K
- TKNO 224.0K
- Earning Date
- RIGL 08-05-2025
- TKNO 08-07-2025
- Dividend Yield
- RIGL N/A
- TKNO N/A
- EPS Growth
- RIGL N/A
- TKNO N/A
- EPS
- RIGL 5.43
- TKNO N/A
- Revenue
- RIGL $267,921,000.00
- TKNO $38,923,000.00
- Revenue This Year
- RIGL $59.93
- TKNO $9.52
- Revenue Next Year
- RIGL N/A
- TKNO $15.20
- P/E Ratio
- RIGL $7.15
- TKNO N/A
- Revenue Growth
- RIGL 105.62
- TKNO 11.40
- 52 Week Low
- RIGL $12.66
- TKNO $4.00
- 52 Week High
- RIGL $43.72
- TKNO $10.37
- Technical
- Relative Strength Index (RSI)
- RIGL 68.57
- TKNO 43.35
- Support Level
- RIGL $39.00
- TKNO $4.22
- Resistance Level
- RIGL $42.08
- TKNO $4.94
- Average True Range (ATR)
- RIGL 2.32
- TKNO 0.29
- MACD
- RIGL -0.37
- TKNO -0.00
- Stochastic Oscillator
- RIGL 53.26
- TKNO 16.75
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About TKNO Alpha Teknova Inc.
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its offer three product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It derives key revenue from United States.